Authors: | Oaknin, A.; Bosse, T. J.; Creutzberg, C. L.; Giornelli, G.; Harter, P.; Joly, F.; Lorusso, D.; Marth, C.; Makker, V.; Mirza, M. R.; Ledermann, J. A.; Colombo, N.; on behalf of the ESMO Guidelines Committee |
Title: | Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up |
Keywords: | immunohistochemistry; cancer survival; cancer surgery; disease course; histopathology; bevacizumab; doxorubicin; advanced cancer; cancer combination chemotherapy; cancer risk; monotherapy; paclitaxel; adjuvant therapy; cancer adjuvant therapy; treatment; cancer staging; outcome assessment; recurrence risk; follow up; methodology; follow-up studies; endometrial cancer; antineoplastic agent; cancer incidence; endometrial neoplasms; endometrium cancer; carboplatin; metastasis; prevalence; practice guideline; oncology; protein p53; risk factor; high risk patient; risk assessment; cancer hormone therapy; diagnosis; antiangiogenic therapy; long term care; medical oncology; recurrent disease; external beam radiotherapy; cancer control; estrogen receptor; progesterone receptor; immunosurveillance; cyclin dependent kinase inhibitor; mismatch repair protein; endometrium tumor; follow-up; programmed death 1 ligand 1; gestagen; intermediate risk patient; molecularly targeted therapy; dna directed dna polymerase epsilon; mortality rate; low risk patient; cancer prognosis; long term survival; epidemiological data; lenvatinib; humans; human; female; article; pembrolizumab; vaginal brachytherapy; esmo clinical practice guideline; dostarlimab |
Journal Title: | Annals of Oncology |
Volume: | 33 |
Issue: | 9 |
ISSN: | 0923-7534 |
Publisher: | Oxford University Press |
Date Published: | 2022-09-01 |
Start Page: | 860 |
End Page: | 877 |
Language: | English |
DOI: | 10.1016/j.annonc.2022.05.009 |
PUBMED: | 35690222 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Article -- Export Date: 3 October 2022 -- Source: Scopus |